Absci Investor Presentation Deck

Absci's workflow identifies antigens targeted by exceptional immune responses A Highly Productive Workflow* ● >6,600 Reconstructed antibodies >250 Hits under evaluation *Information as of 02/09/2023 ABSCI CORPORATION 2023 ALL RIGHTS RESERVED 22 Antibody/Target pairs Expanded network of health care institutions provides continuous access to patient data (melanoma, colorectal cancer, RA, psoriasis, lupus, etc.) Validated examples in oncology, immunology and infectious diseases Large collection of TLS-derived antibodies targeting cancer specific antigens, cytokine receptors, checkpoint inhibitors and other targets Immuno-oncology 26% 35% Oncology 39% Autoimmunity and Inflammation absci. 32

View entire presentation